首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Cancer Treatment Reviews

Cancer Treatment Reviews杂志,由W.B. Saunders Ltd出版,于1974年创刊,Quarterly,出版语言English,ISSN:0305-7372,E-ISSN:1532-1967。

投稿咨询
Cancer Treatment Reviews
Cancer Treatment Reviews
Cancer Treatment Reviews
SCI SCIE

杂志介绍

JCR分区
Q1
中科院分区
1区
影响因子
10.6
CiteScore
17.7
期刊收录
SCI、SCIE

Cancer Treatment Reviews(中文译名:《癌症治疗评论》),ISSN:0305-7372,EISSN:1532-1967,是W.B. Saunders Ltd出版的国际性学术期刊,创刊于1974年,以Quarterly形式稳定发行,2026年总发文量约118篇。该刊采用非OA开放访问,学科归属为医学 - 肿瘤学。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达10.6,2025年期刊CiteScore为17.7,2025年期刊自引率约0.9%,在中科院期刊分区体系中位列医学大类1区TOP 期刊,在所属学科领域具备高学术影响力与国际认可度。Cancer Treatment Reviews长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期约6月,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,ItalyUSA、England、Spain、France、Netherlands、GERMANY (FED REP GER)等为核心发文国家与地区;UNICANCERUNIVERSITY OF MILAN、UNIVERSITY OF TORONTO、UNIVERSITY OF TEXAS SYSTEM、CIBER - CENTRO DE INVESTIGACION BIOMEDICA EN RED、FONDAZIONE IRCCS ISTITUTO NAZIONALE TUMORI MILAN、IRCCS EUROPEAN INSTITUTE OF ONCOLOGY (IEO)等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区
是 否

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区
是 是

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
1区
ONCOLOGY 肿瘤学
2区
是 是

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 34 / 333

89.9

学科:ONCOLOGY SCIE Q1 53 / 333

84.23

2024-2025年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q1 28 / 328

91.6

学科:ONCOLOGY SCIE Q1 46 / 328

86.13


中国学者近期发文

1
Neoantigen-based dendritic cell vaccines in lung cancer: overcoming immunosuppressive barriers for durable antitumor immunit

Author:Li, Zhang; Zhang, Feiyue; Luyu, Huang; Zhang, Wenqiang; Ismail, Mahmoud; Rueckert, Jens-C

Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 145, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103125

2
Circulating tumor DNA in breast cancer: From technological foundation to clinical implementatio

Author:Lin, Xinyi; Liu, Baiying; Wu, Jing; Shi, Lina; Zhang, Yanyan; Yang, Qiaoyu; Tang, Haiyun; Xu, Shaoting; Gao, Yuxuan; Cui, Jihong; Zhang, Yunjian

Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 144, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103108

3
Targeted precision Strike in Extensive-Stage small cell lung Cancer: Current advances and future Perspectives for Antibody-Drug conjugate

Author:Li, Yuwei; Chen, Kaiyan; Li, Hui; Fan, Yun

Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 143, Issue , pp. -. DOI: 10.1016/j.ctrv.2026.103091

4
Intracranial activity of antibody-drug conjugates in advanced non-small cell lung cancer: What have we accomplished so far

Author:Cheo, Seng Wee; Li, Molly S. C.; Huang, Derek De-Rui; Saw, Stephanie P. L.; Hendriks, Lizza E. L.; Remon, Jordi; Menis, Jessica; Addeo, Alfredo; Voon, Pei Jye

Journal: CANCER TREATMENT REVIEWS. 2026; Vol. 143, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.103083

5
Long and short-term efficacy and safety comparison of nab-paclitaxel versus paclitaxel combined with trastuzumab and pertuzumab for neoadjuvant treatment of HER2-positive breast cancer: A systematic review and meta-analysi

Author:Yuan, Ye; Long, Xin; Wei, Mengya; Chen, Li; Zhang, Ji; Liu, Xumei

Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 138, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102975

6
Chimeric antigen receptor NK cells for breast cancer immunotherap

Author:Wu, Nisha; Yang, Ning; Zhang, Shiqi; Wu, Haoran; Fang, Xuechun; Lin, Wanying; Zhang, Yi; Qi, Xiaowei; Gong, Ying

Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 137, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102943

7
Management approaches for recurrent or metastatic head and neck squamous cell carcinoma after anti-PD-1/PD-L1 immunotherap

Author:Tahara, Makoto; Lim, Darren Wan-Teck; Keam, Bhumsuk; Ma, Brigette; Zhang, Li; Wang, Chaojun; Guo, Ye

Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 136, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102938

8
Operationalizing intermediate clinical endpoints: A pragmatic framework for prostate cancer management trial

Author:Xiong, Xingyu; Zhang, Shiyu; Du, Jiajia; Liao, Xinyang; Yang, Jie; Zheng, Weitao; Xu, Hang; Yang, Lu; Wei, Qiang

Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 136, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102935

9
Managing strategies of chemotherapy and radiotherapy-induced oral mucositi

Author:Wu, Yuqi; Shi, Wenjin; Li, Chunyu; Liu, Xiangfei; Jiang, Yuchen; Qiu, Yan; Chen, Qianming; Luo, Xiaobo

Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 133, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102883

10
Incomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonist

Author:Lin, Jinna; Zheng, Shuqi; Liu, Qiang

Journal: CANCER TREATMENT REVIEWS. 2025; Vol. 133, Issue , pp. -. DOI: 10.1016/j.ctrv.2025.102879


在线咨询

Cancer Treatment Reviews

国际简称:CANCER TREAT REV参考译名:癌症治疗评论

年发文量:118 CiteScore:17.7 是否预警:否 Gold OA文章占比:37.12% 研究类文章占比:0.00%

杂志社联系方式:ELSEVIER SCI LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND, OXON, OX5 1GB

Cancer Treatment Reviews